Because the current Directive will be significantly altered and replaced by a Regulation which is legally binding on all Member States.
The Commission adopted a package of measures on innovation in health. The package consisted of a Communication and two regulation proposals to revise existing legislation on general medical devices and in vitro diagnostic medical devices. In particular, the Directives on active implantable medical devices (90/385/EEC) and on medical devices (93/42/EEC) are intended to be replaced by a Regulation on medical devices, while the Directive on in-vitro diagnostic medical devices (98/79/EC) is intended to be replaced by a Regulation on the same subject.
The revisions therefore affected all kinds of medical devices including in vitro diagnostic medical devices, from home-use items like sticking plasters, pregnancy tests and contact lenses, to X-ray machines, pacemakers, breast implants, hip replacements and HIV blood tests.
This will look at what to expect when the new regulation is implemented. Including: the transition period, Effect on Notified Bodies, Impact of the MDR on Quality Management Systems (QMS), technical documentation, clinical trial requirements, UDI and combination products.
-> Because the current Directive will be significantly altered and replaced by a Regulation which is legally binding on all Member States.
- Clinical Trial Managers
- Regulatory Affairs
- Medical Officers
- The updated Regulation
- Implementation Dates and Transition
- Main changes and Products Affected
- Effect on Medical Device Manufacturers
Posted 11 September 2017 By Zachary Brennan
FDA commissioner Scott Gottlieb on Monday explained to attendees of RAPS’ Regulatory Convergence conference some steps FDA is taking to make the clinical end of drug development more efficient and effective.
Opening with a discussion of the ways in which the gap of time between the discovery of the science behind new treatments and the adoption of such treatments has been shrinking, Gottlieb outlined a few of the ways in which the agency is modernizing its approach to collecting and evaluating clinical information.
And on a day when the discussion of how much it costs to develop a new oncology drug is being hotly debated with the release of a new study, Gottlieb also discussed how the costs of drug development “are also high, and growing.
“There’s been criticism of the various estimates of how much it costs to develop a new drug,” he said, according to the transcript of his speech. “Moreover, on a relative basis, in many cases the costs of early stage drug development has grown at a proportionally faster rate than the cost of late stage drug development. In other words, inflation in early stage drug trials is rising faster than inflation in late stage development.
“By front-loading the cost of drug discovery, the broader biomedical community is making it harder to advance new ideas. It’s economically harder to capitalize the cost of an early stage drug program, relative to funding a later stage project. So frontloading the costs are a recipe for reducing the amount of new ideas that can be advanced.”
Read More information: http://snip.ly/6ude0#http://www.raps.org/Regulatory-Focus/News/2017/09/11/28442/Gottlieb-Targets-Drug-Development-Costs-Clinical-Development-Efficiencies/
Used to paying over $250 for a high quality healthcare webinar from a leading expert on the topic from a reputable provider of professional trainings? Let us change your habit! You no longer have to pay this much. So, how much do you think you need to be paying for top healthcare webinars? $200? $150? $100? None of these. All that you have to pay for a top healthcare webinar is $10!
Yes, no spelling errors here. It is indeed $10. That is all you need to pay for a healthcare webinar from GlobalCompliancePanel, a leading provider of professional trainings for all the areas of regulatory compliance. There is a whole list of top healthcare webinars you can get for $10. There are just so many on offer; you will be spoilt for choice:
Healthcare reform is one of the hot areas of healthcare today, what with many regulations that keep coming up from time to time about this critical sector of the economy. This top healthcare webinar you can get for $10 equips you with many facets of the Affordable Care Act, or what we have come to call Obamacare. What impact will it have on employees and employers? Find out through this webinar.
Healthcare is an area in which FMEA applies very strongly. When something goes wrong at the healthcare provider’s location; it throws the whole system out of gear. Carrying out a thorough failure mode and effects analysis is a great antidote to these problems. Want to find out how to do it? This top healthcare webinar you can get for $10 has the answers.
But one question has not been answered yet: Why is GlobalCompliancePanel doing this? Why is it having this offer now? Well, it is because it wants to ensure that the community of regulatory professionals grows, and grows well. Having been in the professional trainings area for ten years now; it feels this is something it needs to do in order to draw more people into the regulatory trainings network. By offering top healthcare webinars you can get for $10; GlobalCompliancePanel wants to contribute its mite to enhancing and expanding the learning community.
Isn’t this offer of top healthcare webinars you can get for $10 the ideal means to growing up in your career? After all, we spend this amount on myriad things that could be of some use to us, but does this use compare with the enormity of the utility a healthcare webinar gives? These top healthcare webinars you can get for $10 each help you climb your professional ladder. This in turn could help your organization make a name as a responsible and ethical provider of quality products. It could earn it a reputation in the market. When you can accomplish all these through top healthcare webinars you can get for $10, what are you waiting for?